The Molecular Mechanism of Thrombospondin Family Members in Cardiovascular Diseases

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Mar 22

PMID 38516004

Authors

Heng Pan

Xiyi Lu

Di Ye

Yongqi Feng

Jun Wan

Jing Ye

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases have been identified as vital factors in global morbidity and mortality in recent years. The available evidence suggests that various cytokines and pathological proteins participate in these complicated and changeable diseases. The thrombospondin (TSP) family is a series of conserved, multidomain calcium-binding glycoproteins that cause cell-matrix and cell-cell effects via interactions with other extracellular matrix components and cell surface receptors. The TSP family has five members that can be divided into two groups (Group A and Group B) based on their different structures. TSP-1, TSP-2, and TSP-4 are the most studied proteins. Among recent studies and findings, we investigated the functions of several family members, especially TSP-5. We review the basic concepts of TSPs and summarize the relevant molecular mechanisms and cell interactions in the cardiovascular system. Targeting TSPs in CVD and other diseases has a remarkable therapeutic benefit.

References

Stirling E, Terabe M, Wilson A, Kooshki M, Yamaleyeva L, Alexander-Miller M . Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response. J Immunother Cancer. 2022; 10(11). PMC: 9685258. DOI: 10.1136/jitc-2022-004712. View

Meijers W, de Boer R . Common risk factors for heart failure and cancer. Cardiovasc Res. 2019; 115(5):844-853. PMC: 6452432. DOI: 10.1093/cvr/cvz035. View

Leong D, Joseph P, Mckee M, Anand S, Teo K, Schwalm J . Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017; 121(6):695-710. DOI: 10.1161/CIRCRESAHA.117.311849. View

Thaunat O, Louedec L, Graff-Dubois S, Dai J, Groyer E, Yacoub-Youssef H . Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Transplantation. 2008; 85(2):281-9. DOI: 10.1097/TP.0b013e318160500a. View

Fu Y, Huang Y, Yang Z, Chen Y, Zheng J, Mao C . Cartilage oligomeric matrix protein is an endogenous β-arrestin-2-selective allosteric modulator of AT1 receptor counteracting vascular injury. Cell Res. 2021; 31(7):773-790. PMC: 8249609. DOI: 10.1038/s41422-020-00464-8. View

Stenina-Adognravi O . Thrombospondins: old players, new games. Curr Opin Lipidol. 2013; 24(5):401-9. PMC: 3935726. DOI: 10.1097/MOL.0b013e3283642912. View

Muppala S, Xiao R, Krukovets I, Verbovetsky D, Yendamuri R, Habib N . Thrombospondin-4 mediates TGF-β-induced angiogenesis. Oncogene. 2017; 36(36):5189-5198. PMC: 5589494. DOI: 10.1038/onc.2017.140. View

Wang H, Yuan Z, Wang B, Li B, Lv H, He J . COMP (Cartilage Oligomeric Matrix Protein), a Novel PIEZO1 Regulator That Controls Blood Pressure. Hypertension. 2022; 79(3):549-561. DOI: 10.1161/HYPERTENSIONAHA.121.17972. View

Weng T, Huang S, Yen M, Lin C, Chen Y, Lin C . A novel cancer therapeutic using thrombospondin 1 in dendritic cells. Mol Ther. 2013; 22(2):292-302. PMC: 3918914. DOI: 10.1038/mt.2013.236. View

10.

Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y . Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin αβ/CD36-mediated activation of the MAPK pathway. Cancer Lett. 2021; 528:59-75. DOI: 10.1016/j.canlet.2021.12.025. View

11.

Futagami Y, Sugita S, Vega J, Ishida K, Takase H, Maruyama K . Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells. J Immunol. 2007; 178(11):6994-7005. DOI: 10.4049/jimmunol.178.11.6994. View

12.

Isenberg J, Romeo M, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L . Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007; 100(5):712-20. DOI: 10.1161/01.RES.0000259579.35787.4e. View

13.

Fu Y, Gao C, Liang Y, Wang M, Huang Y, Ma W . Shift of Macrophage Phenotype Due to Cartilage Oligomeric Matrix Protein Deficiency Drives Atherosclerotic Calcification. Circ Res. 2016; 119(2):261-76. DOI: 10.1161/CIRCRESAHA.115.308021. View

14.

Venkatraman L, Chia S, Narmada B, White J, Bhowmick S, Dewey Jr C . Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1. Biophys J. 2012; 103(5):1060-8. PMC: 3433618. DOI: 10.1016/j.bpj.2012.06.050. View

15.

Mustonen E, Ruskoaho H, Rysa J . Thrombospondins, potential drug targets for cardiovascular diseases. Basic Clin Pharmacol Toxicol. 2012; 112(1):4-12. DOI: 10.1111/bcpt.12026. View

16.

Fang J, Chopp M, Xin H, Zhang L, Wang F, Golembieski W . Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice. J Cereb Blood Flow Metab. 2021; 41(10):2583-2592. PMC: 8504962. DOI: 10.1177/0271678X211007958. View

17.

Stein E, Miller T, Ivins-OKeefe K, Kaur S, Roberts D . Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47. Sci Rep. 2016; 6:19684. PMC: 4728557. DOI: 10.1038/srep19684. View

18.

Kresoja K, Rommel K, Wachter R, Henger S, Besler C, Kloting N . Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2021; 23(10):1633-1644. DOI: 10.1002/ejhf.2291. View

19.

van Almen G, Swinnen M, Carai P, Verhesen W, Cleutjens J, Dhooge J . Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol. 2011; 51(3):318-28. DOI: 10.1016/j.yjmcc.2011.05.010. View

20.

Frolova E, Pluskota E, Krukovets I, Burke T, Drumm C, Smith J . Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res. 2010; 107(11):1313-25. PMC: 2993182. DOI: 10.1161/CIRCRESAHA.110.232371. View